7th AML Academy and SAL autumn meeting 2024
Study Alliance Leukemia – AML Cooperative Group – CELL

Scandic Hotel Frankfurt/Main or online via Zoom
14th/15th November 2024

Dear members of the SAL and AMLCG study groups,
Dear members of CELL,

we are pleased to invite you to the 7th AML Academy and Fall Meeting of the SAL and AMLCG Study Groups on November 14–15, 2024.

The event will be hybrid at the Scandic Hotel in Frankfurt/Main and online via Zoom. More information will follow, but please keep the date free in your calendar.

We are already looking forward to our meeting.

Kind regards,

Prof. Dr. med. Martin Bornhäuser
Medical Clinic and Polyclinic 1, University Hospital Dresden

Prof. Dr. med. Christoph Röllig
Medical Clinic and Polyclinic 1, University Hospital Dresden
SAL Study Center

Thursday, 14th November 2024

13:00–13:10
Welcome


AML Academy I

13:10–13:30
Infections in AML patients during remission induction
Sabine Ehrlich

13:30–13:50
Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in AML
Julian Ronnacker

13:50–14:10
Histone demethylation tones down leukemia through innate immunity
Mari F. Arteaga

14:10–14:25
German Cancer Registries and the SAL-AML Registry – Any correlations?
David Baden

14:25–14:45
AI for diagnostics and risk stratification in AML
Moritz Middeke

15:15–15:35
Long-term survival after AML treatment
Klaus Metzeler

15:35–16:00
Treatment of relapsed/refractory AML: non-intensive approaches and other options
Tim Sauer

16:00–16:30
Transplant in AML: Standards and open questions
Gesine Bug


AML Academy II

17:30–17:30
Clonal Hematopoiesis: What’s new and are there real clinical implications?
Gerwin Huls

17:30–18:00
AML in first CR: What to do next?
Richard Dillon

18:00–18:45
How I treat high-risk AML now and in 5 years
David Sallman

18:45–18:55
Closing remarks

From 19:30
Networking dinner

Friday, 15th November 2024


SAL-AMLCG Steering Committee Meeting

08:00–10:00


Joint Study Group Meeting of SAL, AMLCG

10:30–13:00
Updates on current, past and future projects and trials

Break

Joint Study Group Meeting of SAL, AMLCG

14:00–16:00
Updates on current, past and future projects and trials


 

Jazz Pharmaceuticals Germany GmbH presents:

AbbVie Deutschland GmbH & Co. KG presents:

Bristol-Myers Squibb GmbH & Co. KGaA presents:

Chairs

Prof. Dr. med. Christoph Röllig
Prof. Dr. med. Martin Bornhäuser

Universitätsklinikum Carl Gustav Carus Dresden
Medizinische Klinik und Poliklinik der TU Dresden
Fetscherstraße 74
01307 Dresden

Organizer

GWT-TUD GmbH
Freiberger Straße 33
01067 Dresden

Meeting times

AML Academy
Thursday, 14th November 2024
13:00–19:15 h

SAL autumn meeting
Friday, 15th November 2024
08:00–10:00 h SAL–AMLCG Steering Committee Meeting
10:30–16:00 h Joint Study Group Meeting of SAL, AMLCG

Place

Scandic Hotel Frankfurt Museumsufer
Wilhelm-Leuschner-Straße 44, 60329 Frankfurt am Main

or online via Zoom

Juliana Binder
project manager

Mobile: +49 151 23 33 79 72
Phone: +49 351 25 933 211

GWT-TUD GmbH
Fachbereich Medizin

BioInnovationsZentrum
Tatzberg 47/49
01307 Dresden

Jazz Pharma GmbH30.000 €
AbbVie Deutschland GmbH & Co. KG20.000 €
Daiichi Sankyo Deutschland GmbH10.000 €
Otsuka Pharma GmbH10.000 €
Pfizer10.000 €
SERVIER Deutschland GmbH10.000 €
Astellas Pharma GmbH5.000 €
BeiGene Ltd.5.000 €
Bristol-Myers Squibb GmbH & Co. KGaA5.000 €
Neovii Biotech GmbH5.000 €
Stemline Therapeutics Switzerland GmbH5.000 €

We like to thank the sponsors for their contributions. The stated amounts are charged exclusively for advertising purposes and stand costs. If you are interested in sponsoring, please contact the event management.

The sponsors that are subject to the FSA code are based on the FSA code, which obliges to transparency. The monetary benefits are documented and published on their website.